SCHEMBL16477276

SCHEMBL16477276

COc1ccc2oc3ccc(C)cc3c(=O)c2c1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.83
KDM4E B2RXH2 5/20 0.83
ALDH1A1 P00352 5/20 0.83
HPGD P15428 4/20 0.83
NPC1 O15118 3/20 0.83
RAB9A P51151 3/20 0.83
SMN1; SMN2 Q16637 3/20 0.83
CASP3 P42574 1/20 0.83
SENP8 Q96LD8 1/20 0.83
SENP7 Q9BQF6 1/20 0.83
SENP6 Q9GZR1 1/20 0.83
MAOA P21397 3/20 0.71
CSNK2A2 P19784 2/20 0.62
CSNK2B P67870 2/20 0.62
CSNK2A1 P68400 2/20 0.62
HSD17B10 Q99714 3/20 0.59
KCNA5 P22460 1/20 0.58
KCNH2 Q12809 1/20 0.58
TP53 P04637 2/20 0.58
ATM Q13315 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1567209 0.93 MAOA (0.86) MAPTKDM4EALDH1A1HPGDNPC1
SCHEMBL28401540 0.92 NPC1 (0.76) MAPTKDM4EALDH1A1HPGDNPC1
SCHEMBL11726836 0.92 ALDH1A1 (0.71) MAPTKDM4EALDH1A1HPGDNPC1
SCHEMBL2161251 0.91 ALDH1A1 (1.00) MAPTKDM4EALDH1A1HPGDNPC1
SCHEMBL29619913 0.91 ALDH1A1 (1.00) MAPTKDM4EALDH1A1HPGDNPC1
SCHEMBL20317284 0.88 KDM4E (0.69) MAPTKDM4EALDH1A1HPGDNPC1
SCHEMBL20317282 0.88 KDM4E (0.69) MAPTKDM4EALDH1A1HPGDNPC1
SCHEMBL20346707 0.88 MAPT (0.65) MAPTKDM4EALDH1A1HPGDNPC1
SCHEMBL1611070 0.86 ALPG (0.59) MAPTKDM4EALDH1A1HPGDNPC1
SCHEMBL7331388 0.85 KDM4E (0.86) MAPTKDM4EALDH1A1HPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220251106-A1 ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2022-08-11 US disclosed
US-9163002-B2 Methodology for the synthesis of xanthones UNIVERSITY OF SOUTH CAROLINA (US) 2015-10-20 US disclosed
US-9163002-B2 Methodology for the synthesis of xanthones UNIVERSITY OF SOUTH CAROLINA (US) 2015-10-20 US disclosed
US-20140107354-A1 New Methodology for the Synthesis of Xanthones UNIVERSITY OF SOUTH CAROLINA 2014-04-17 US disclosed
US-20140107354-A1 New Methodology for the Synthesis of Xanthones UNIVERSITY OF SOUTH CAROLINA 2014-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140107354-A1 New Methodology for the Synthesis of Xanthones XDH, TYR, NISCH MAPT 2203/4885KDM4E 1101/4885ALDH1A1 857/4885
US-20220251106-A1 ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE OR51E2, TAS2R38, SOD1 MAPT 2879/4885KDM4E 4454/4885ALDH1A1 1459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.